NZ760036A - Dihydro-pyrrolo-pyridine derivatives - Google Patents

Dihydro-pyrrolo-pyridine derivatives

Info

Publication number
NZ760036A
NZ760036A NZ760036A NZ76003618A NZ760036A NZ 760036 A NZ760036 A NZ 760036A NZ 760036 A NZ760036 A NZ 760036A NZ 76003618 A NZ76003618 A NZ 76003618A NZ 760036 A NZ760036 A NZ 760036A
Authority
NZ
New Zealand
Prior art keywords
compound
pyrrolo
dihydro
pyridine derivatives
compounds
Prior art date
Application number
NZ760036A
Other versions
NZ760036B2 (en
Inventor
Lei Zhang
Adam Gilbert
Matthew Frank Brown
Michael Aaron Brodney
Christopher Ryan Butler
Erik Alphie Lachapelle
Laura Ann Mcallister
Elizabeth Mary Beck
Daniel Paul Uccello
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ760036A publication Critical patent/NZ760036A/en
Publication of NZ760036B2 publication Critical patent/NZ760036B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer’s Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Claims (9)

What is claimed is:
1. A compound having the structure: (+/-)-trans- , or a pharmaceutically acceptable salt thereof.
2. The nd of claim 1, wherein the compound is: (+/-)-trans- .
3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of: (+/-)-trans- .
4. A compound having the structure: (+)-trans- , or a pharmaceutically able salt thereof.
5. The compound of claim 4, wherein the compound is: (+)-trans- .
6. The compound of claim 4, wherein the compound is a pharmaceutically acceptable salt of: (+)-trans- .
7. A compound having the structure: (-)-trans- , or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, wherein the compound is ans- .
9. The compound of claim 7, wherein the compound is a pharmaceutically acceptable salt of: (-)-trans- .
NZ760036A 2018-06-14 Dihydro-pyrrolo-pyridine derivatives NZ760036B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523306P 2017-06-22 2017-06-22
PCT/IB2018/054390 WO2018234953A1 (en) 2017-06-22 2018-06-14 Dihydro-pyrrolo-pyridine derivatives

Publications (2)

Publication Number Publication Date
NZ760036A true NZ760036A (en) 2025-05-30
NZ760036B2 NZ760036B2 (en) 2025-09-02

Family

ID=

Also Published As

Publication number Publication date
IL271290A (en) 2020-01-30
HUE060914T2 (en) 2023-04-28
KR20200013783A (en) 2020-02-07
CN110944998A (en) 2020-03-31
EP3642202A1 (en) 2020-04-29
BR112019026955A2 (en) 2020-06-30
JP2020524687A (en) 2020-08-20
US11198692B2 (en) 2021-12-14
DK3642202T3 (en) 2023-01-30
CN110944998B (en) 2022-08-16
IL271290B2 (en) 2023-11-01
PL3642202T3 (en) 2023-03-13
FI3642202T3 (en) 2023-03-01
IL271290B1 (en) 2023-07-01
TW201920166A (en) 2019-06-01
US20200262833A1 (en) 2020-08-20
ES2937236T3 (en) 2023-03-27
JP7263266B2 (en) 2023-04-24
WO2018234953A1 (en) 2018-12-27
PT3642202T (en) 2023-02-02
SG11201913014YA (en) 2020-01-30
AU2018287787A1 (en) 2020-01-16
TWI680128B (en) 2019-12-21
CA3066986A1 (en) 2018-12-27
EP3642202B1 (en) 2022-11-02
MX2019015371A (en) 2020-07-20

Similar Documents

Publication Publication Date Title
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
MX2019015371A (en) Dihydro-pyrrolo-pyridine derivatives.
MX2022012317A (en) Oxysterols and methods of use thereof.
MX2020013099A (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
JOP20190151B1 (en) Amino-triazolopyridine compounds and their use in cancer treatment
EA201890650A1 (en) DERIVATIVES 8- [6- [3- (amino) propoxy] -3-pyridyl] -1-ISOPROPYL-imidazo [4,5-c] quinolin-2-one as selective modulators of kinase MUTATION ataxia-telangiectasia (ATM) FOR CANCER TREATMENT
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018005445A (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
EA201691428A1 (en) BICYCLIC HETEROCYCLIC DERIVATIVES AS IRAK4 INHIBITORS
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
PE20130010A1 (en) DERIVATIVE OF 1,3,4,8-TETRAHIDRO-2H-PIRIDO [1,2-A] PIRAZINE AS AN INHIBITOR OF HIV INTEGRASE
MX2009011830A (en) Amino-heterocyclic compounds.
MX2020011652A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
GEAP202215499A (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2019010756A (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors.
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
PH12017501699B1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof

Legal Events

Date Code Title Description
PSEA Patent sealed